Abstract
Grade 2 NET liver metastases have less durable PFS than low-grade tumors following embolotherapy (12 months vs. 18 months, Chen 2017). Capecitabine-temozolomide (CapTem) is an effective regimen in NETs and both drugs are radiosensitizers. A feasibility study of integrated CapTem and Y-90 transarterial radioembolization (TARE) demonstrated tolerability with expected additive toxicities and encouraging ORR and PFS (Soulen 2018). This study expands that report to a larger cohort with oncologic follow-up.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
